Patients with pollen-related allergic rhinitis prefer on demand antihistamines, with treatment preferences differing markedly ...

The AIM-listed immunotherapy specialist will present three posters at the AAAAI Annual Meeting in Philadelphia this week ...

Allergic rhinitis shows dual effects on COVID 19 symptoms, while sublingual immunotherapy modifies respiratory and fever risk ...

Recent research has revealed that allergic rhinitis (AR) can significantly influence COVID-19 symptom patterns, showing both protective and risk associations, while sublingual immunotherapy (SLIT) ...

SK Chemicals said on the 3rd that it signed a joint sales contract with Kyungnam Pharm for the allergic rhinitis treatment "Noseal Soft Capsule." Under the agreement, Kyungnam Pharm will take charge ...

By type, the subcutaneous immunotherapy segment held the highest share in the year 2023. Subcutaneous immunotherapy helps reduce allergy symptoms. It is known to offer sustained relief even after ...

According to MarketsandMarkets™, the Allergy Diagnostics Market is projected to grow from about USD 6.80 billion in 2026 to ...

Early in 2026, Polyrizon Ltd. (Nasdaq: PLRZ), a pre-clinical-stage biotechnology company developing intranasal protective solutions, completed the branding process for its lead intranasal allergy ...

Neurent Medical today announced positive findings from a randomized controlled trial evaluating its Neuromark system.

Altamira Medica’s Bentrio nasal spray receives notice of allowance from Japan Patent Office: Hamilton, Bermuda Monday, February 16, 2026, 16:00 Hrs [IST] Altamira Therapeutics L ...

Montelukast is a leukotriene receptor antagonist approved for the prophylactic and chronic treatment of asthma and the relief of allergic rhinitis.

HAMILTON, BM / ACCESS Newswire / February 13, 2026 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCID:CYTOF), ...